Peer-Reviewed Publication in Clinical & Experimental Allergy Reveals Potential Disease-Modifying Effect of Mabylon’s Allergen-Neutralizing Antibodies
— Allergen-specific, human-derived IgG4 antibodies prevent allergic reactions by neutralizing allergens and redirecting them toward tolerance-associated immune pathways
— Mechanism-of-action observed across different allergy indications
— Study provides preclinical proof-of-concept for Mabylon’s proprietary allergen-neutralizing approach
Mabylon AG, a leader in the discovery and development of human-derived, half-life extended multi-specific antibodies, today announced the publication of a new study in Clinical & Experimental Allergy (http://doi.org/10.1111/cea.70459), the official journal of the British Society for Allergy & Clinical Immunology (BSACI).
Mabylon presents novel allergen-neutralization approach at the Food Allergy Science Initiative (FASI 10) at the Broad Institute
Mabylon AG was invited to present its novel allergen-neutralization approach at FASI’s 10-Year Anniversary Research Summit at the Broad Institute.
CSO Niccolo Pengo presented Mabylon’s work on long-acting, multispecific, human-derived antibodies designed to neutralize allergens before they can trigger the allergic cascade.
The approach differs from traditional desensitization strategies in that it targets the allergens themselves rather than endogenous immune pathways or repeatedly exposing patients to the allergen. Mabylon’s antibodies are designed to provide prophylactic protection and sustained efficacy with only a few subcutaneous injections. Read more…
1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson’s Disease Candidate ‘1ST-104’
— Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investment
— Collaboration leverages 1STBIO’s Type 2 LRRK2/c-Abl dual inhibitor to advance next-generation Parkinson’s treatment
1ST Biotherapeutics, Inc. (“1STBIO”) and SK Biopharmaceuticals Co., Ltd. (“SKBP”) today announced that they have entered into an exclusive global licensing agreement and strategic equity investment (SI) partnership to advance 1ST-104, a novel drug candidate for the treatment of Parkinson’s disease.
